Isosorbide 5-mononitrate. A review of a sustained-release formulation (Imdur®) in stable angina pectoris

Drugs

Volumn 57, Issue 2, 1999, Pages 261-277

  Gunasekara, Nishan S ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE;

ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERANCE; FATIGUE; HEADACHE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PROPHYLAXIS; QUALITY OF LIFE; REBOUND; RHINITIS; ST SEGMENT DEPRESSION; SUSTAINED RELEASE PREPARATION; VASODILATATION; VERTIGO; VIRUS INFECTION;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; DELAYED-ACTION PREPARATIONS; DRUG SYNERGISM; HUMANS; ISOSORBIDE DINITRATE; PATIENT COMPLIANCE; QUALITY OF LIFE;

EID: 0032972317     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957020-00016     Document Type: Article

References (53)

1. Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993; 72: 871-6
2. Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994; 120 (5): 353-9
3. Jonsson UE. Development of long-acting nitrate delivery systems. Eur J Clin Pharmacol 1990; 38 Suppl. 1: S15-9
4. Sjögren J. Studies on a sustained release principle based on an inert plastic matrix. Acta Pharm Suec 1971 (8): 153-68
5. Task Force of the European Society of Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997 Mar; 18: 394-413
6. Brunelli C, Cristofani R, L'Abbate A. Long-term survival in medically treated patients with ischaemic heart disease and prognostic importance of clinical and electrocardiographic data. Eur Heart J 1989; 10: 292-303
7. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris: the Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76-81
8. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17: 104-12
9. Torfgärd KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1994 Oct; 8: 701-17
10. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. Drug Ther 1998; 338 (8): 520-31
11. Fung H-L, Chung S-J, Bauer JA, et al. Biochemical mechanism of organic nitrate action. Am J Cardiol 1992; 70: 4B-10B
12. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation 1993; 87: 1461-7
13. Abrams J. Mechanisms of action of the organic nitrates in the treatment of myocardial ischaemia. Am J Cardiol 1992; 70: 30B-42B
14. Wagner F, Siefert F, Trenk D, et al. Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. Eur J Clin Pharmacol 1990; 38 Suppl. 1: S53-9
15. Parker JD. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol 1996 Nov; 28: 631-8
16. Wisenberg G, Roks C, Nichol P, et al. Sustained effect of and lack of development of tolerance to controlled-release isoorbide-5-mononitrate in chronic stable angina pectoris. Am J Cardiol 1989 Sep 15; 64: 569-76
17. Iversen HK, Nielsen TH, Garre K, et al. Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate. Eur J Clin Pharmacol 1992 Jan; 42: 31-5
18. Kampmann JP. Pharmacokinetics of various preparations of organic nitrates. Drugs 1987; 33 Suppl. 4: 5-8
19. Chasseaud LF. Isosorbide 5-mononitrate pharmacokinetics. Cardiology 1987; 74 Suppl. 1: 6-11
20. Jonsson UE. Various administration forms of nitrates and their possibilities. Drugs 1987; 33 Suppl. 4: 23-31
21. Kosoglou T, Patrick JE, Cohen A, et al. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. Clin Ther 1995 Mar-Apr; 17: 241-51
22. Rutherford JD. Nitrate tolerance in angina therapy: how to avoid it. Drugs 1995 Feb; 49: 196-9
23. Kertland H. Nitrate tolerance - mechanisms and prevention. Conn Med 1993; 57 (4): 232-4
24. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther 1996 (10): 735-42
25. Kosoglou T, Kazierad DJ, Schentag JJ, et al. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. J Clin Pharmacol 1995 Feb; 35: 151-8
26. Nyberg G, Blychert L-O, Jonsson UE. Pharmacokinetics of isosorbide-5-mononitrate in a controlled-release (Durules) formulation. Br J Clin Pharmacol 1985; 20 (5): 541P
27. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993 Dec 1; 72: 1249-56
28. Glasser SP, Imdur Study Group. Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. Am J Cardiol 1997 Dec 15; 80: 1546-50
29. Uusitalo A, Keyriläinen O, Harkonen R, et al. Anti-anginal efficacy of a controlled-release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic β-blockade. Acta Med Scand 1988; 223: 219-25
30. Nordlander R, Walter M, Swedish Multicentre Group. Once-versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris: a randomized, double-blind, cross-over study. Eur Heart J 1994 Jan; 15: 108-13
31. Svendsen JH, Aldershvile J, Abildgaard U, et al. Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to β-blocking agents in patients with stable angina pectoris. J Cardiovasc Pharmacol 1989 Sep; 14: 358-63
32. Deeg P, Becker B, Feldmann M, et al. Antianginal effect of isosorbide-5-mononitrate given as monotherapy in angina pectoris: a comparison of two different once-daily formulations. Drug Invest 1993 Oct; 6: 231-6
33. Eteiba H, Hutton I, Foale RA, et al. Acute and chronic effects of once-daily isosorbide-5-mononitrate on the exercise capacity of patients with angina pectoris treated with a beta-blocking drug. Br J Clin Pract 1991; 45 (3): 185-8
34. Seabra-Gomes R, Aleixo AM, Adao M, et al. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris. Am J Cardiol 1990 Jun 1; 65: 1308-12
35. Engby B, Dehlholm B, Bötker H-E, et al. Stable angina treated with isosorbide-5-mononitrate, Durules, diltiazem or the combination [abstract]. Eur Heart J 1989 Aug; 10: 72
36. Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994 Aug; 8: 611-23
37. Nyberg G, Carlens P, Lindström E, et al. The effect of isosorbide-5-mononitrate (5-ISMN) Durules registered on exercise tolerance in patients with exertional angina pectoris: a placebo controlled study. Eur Heart J 1986; 7 (10): 835-42
38. Parker JO. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate. Can J Cardiol 1991 Apr; 7: 125-30
39. Olsson G, Allgén J, Amtorp O, et al. Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation. Eur Heart J 1992 Jun; 13: 814-7
40. Rehnqvist N, Olsson G, Engvall J, et al. Abrupt withdrawal of isosorbide-5-mononitrate in Durules (Imdur) after long term treatment in patients with stable angina pectoris. Eur Heart J 1988 Dec; 9: 1339-47
41. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994 Sep-Oct; 22: 266-72
42. Beran YM, Richardson PDI. Enhanced control of angina pectoris in general practice: once-daily treatment with isosorbide mononitrate (Imdur) as Durules. Clin Trials J 1989; 26 (1): 23-32
43. Meffert M, Paeckelmann I-M. Experience of long term treatment and different dosage regimens of isosorbide-5-mononitrate. Drugs 1987; 33 Suppl. 4: 104-10
44. Astra Hässle AB. Slide Resource Imdur. Astra Hässle AB (Mölndal), 1996. (data on file)
45. Thadani U, Chohan A. Chronic stable angina pectoris: strategies for effective drug therapy. Postgrad Med 1995 Dec; 98: 175-88
46. Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8-16
47. Beyerle A, Reiniger G, Rudolph W. Long-acting, marked anti-ischemic effect maintained unattenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained-release form. Am J Cardiol 1990 Jun 15; 65: 1434-7
48. Guzik J, Kanopka M, Maciejewicz J, et al. Sustained-release isosorbide-5-mononitrate improves exercise capacity 30 minutes after oral application. Clin Drug Invest 1997 Aug; 14: 117-24
49. Kenedi P, Gathmann-Lewik U. Dose-effect relationship amongst three different sustained-release forms of isosorbide 5-mononitrate in patients with coronary artery disease. Cardiology 1987; 74 Suppl. 1: 29-33
50. Heepe W, Gathmann-Lewik U. Antianginal efficacy and tolerability of 50 mg sustained-release isosorbide 5-mononitrate in an open twelve-month observation study. Cardiology 1987; 74 Suppl. 1: 34-9
51. Ahmadinejad M, Eghbal B, Sorgenicht W, et al. Slow-release isosorbide-5-mononitrate - a new once daily therapeutic modality for angina pectoris. Eur Heart J 1988 Jan; 9 Suppl. A: 135-9
52. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989; 13 (4): 786-95
53. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin 1991; 9 (1): 73-87